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Abstract
Background: More potent antitumor activity is desired in Interferon (IFN)-treated cancer patients. This could be
achieved by combining IFN alpha and IFN gamma. The aim of this work was to characterize the pharmacokinetics
and pharmacodynamics of a novel formulation containing a co-formulated combination of IFNs alpha-2b and
gamma (CIGB-128-A).
Methods: A group of nine healthy male subjects received intramuscularly 24.5 × 106 IU of CIGB-128-A. IFN
concentrations were evaluated for 48 h. Serum neopterin, beta2-microglobulin (β2M) and 2′–5′ oligoadenylate
synthetase (2′–5′ OAS), classical IFN-inducible serum markers, were measured during 192 h by enzyme
immunoassay and body temperature was used as pharmacodynamic variable as well.
Results: Concerning pharmacokinetics, serum IFNs’ profiles were better fitted to a mono-compartmental model
with consecutive zero order and first order absorption, one bioavailability value. No interferences by simultaneous
administered IFNs were observed in their typical similar systemic profiles. Neopterin and β2M time profiles showed
a delay that was efficiently linked to pharmacokinetics by means of a zero order absorption rate constant. Neopterin
level was nine-fold higher than initial values, 48 h post-administration, an increment not described before. At this time,
mean serum β2M peaked around the double from baseline. Serum concentrations of the enzyme 2′–5′ OAS was still
elevated on the 8 day post-injection. The formulation was well tolerated. Most frequent adverse reactions were fever,
headache, arthralgia and lymphopenia, mostly mild.
Conclusions: The administration of co-formulated IFN alpha-2b and IFN gamma likely provides improved
pharmacodynamic properties that may be beneficial to treat several malignancies.
Trial registration: Cuban Public Registry of Clinical Trials RPCEC00000118, May 24, 2011.
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Background
Approaches to improve efficacy, tolerance and patient’s
compliance and quality of life are permanent issues in
pharmacological therapy. Some efforts have succeeded
in favoring the bioavailability of the modified drug. Other
actions are based on extending the systemic half-life
through slower absorption.
Interferons (IFNs), like other low molecular weight
protein drugs, have a relatively short half-life. Their
conjugation to polyethylene-glycol (PEG) represented a
favorable step forward to face this drawback [1]. Never-
theless, improved pharmacodynamics by the combin-
ation of two agents that have the potential to act
synergistically can be another reasonable alternative.
In that sense, IFN alpha-2b and IFN gamma have rec-
ognized synergistic antiproliferative effects on several
tumor cell lines [2] based on the expression and activa-
tion of several IFN regulated genes [3]. The physical
interaction between both IFN receptor complexes seems
to be the first step for triggering intracellular signals that
promote the potentiation of biological activities between
both IFNs [4, 5].
The experience of the Center for Genetic Engineering
and Biotechnology (CIGB, in Spanish) in the develop-
ment of several formulations that contain recombinant
molecules has allowed to obtain a novel formulation
(CIGB-128-A) based on the combination of IFNs alpha-
2b and gamma mixed in antiproliferative synergistic pro-
portions defined in vitro [6]. The peri- and intralesional
administration of the co-formulated IFNs was safe and
effective for the treatment of elder patients with ad-
vanced, recurrent or resistant to previous treatments
basal and squamous cell skin carcinomas [7]. In patients
with mycosis fungoides, a similar IFN combination did
not modify the kinetics of individual IFNs’ concentrations,
but it produced a significant increment in neopterin
serum levels, a well-known pharmacodynamic measure in
IFN studies [8].
As part of CIGB-128-A biological characterization, it
was necessary to carry out a clinical study in healthy
male subjects to integrally analyze pharmacokinetics and
pharmacodynamics, using available modeling tools. This
population has a less inter-individual variability than on-
cologic patients. In order to describe the kinetic behavior
of IFN-induced response, neopterin, β2-microglobulin
(β2M), 2′–5′ oligoadenylate synthetase (2′–5′ OAS) as
well as body temperature were used as pharmacodynamic
variables.
Methods
A phase one clinical trial was carried out at the National
Center for Toxicology, in Havana, a certified reference
unit for this type of studies.
Subjects
Inclusion criteria were: no history of chronic diseases,
no acute illness in the previous 30 days, no symptoms or
signs at physical examination and laboratory tests, and
no presence of HIV and hepatitis B and C virus infection
markers in serum. Toxic habits, history of hypersensibil-
ity to any drug, treatment with any IFN formulation in
the previous 6 months or with any drug in the previous
15 days, surgical intervention in the previous 6 months
and blood donations in the previous 2 months were ex-
clusion criteria. Subjects could withdraw from the trial
voluntarily, due to occurrence of severe adverse reac-
tions, or by the appearance of any exclusion criteria.
IFN formulation
CIGB-128-A, Heber Biotec, Havana, a stabilized lyophi-
lized powder formulation was used. Each vial contains 3
and 0.5 × 106 IU of human recombinant IFNs alpha-2b
and gamma, respectively, both produced in E. coli, tre-
halose, succinic acid and human serum albumin.
Study design
Each volunteer received 24.5 × 106 IU of CIGB-128-A
intramuscularly, in the gluteus region. This represents
21 × 106 IU of IFN alpha-2b and 3.5 × 106 IU of IFN
gamma. For this, the content of seven vials was diluted
in 2 mL of water for injection. Detectable serum levels
of both IFNs and their surrogate markers were expected
at this dose level. The product was administered early in
the morning after overnight fasting. Simultaneously with
CIGB-128-A injection and thereafter, volunteers received
oral antipyretic medication in order to mitigate flu-like
symptoms produced by IFN. Volunteers were regularly
checked for vital signs and adverse manifestations dur-
ing the study. They were hospitalized during the first
48 h, thereafter ambulatory monitoring and blood sam-
pling continued until 8 days.
Laboratory evaluations
For IFN alpha-2b and IFN gamma measurements, sam-
ples were collected by venipuncture before injection and
after 2, 3, 4, 6, 7, 8, 10, 12, 14, 16, 24, 36, and 48 h.
Neopterin, β2M and 2′–5′ OAS determinations in serum
were extended until 192 h after injection. These vari-
ables were assessed before injection and after 6, 12, 24,
48, 72, 96, 120, 168, and 192 h after. Some routine
hematological (hemoglobin, platelet, leukocyte counts)
and biochemical (hepatic enzymes, creatinine) determi-
nations were evaluated for safety during the sampling
period.
All the pharmacological variables were measured using
commercially available enzyme immunoassay (EIA)
kits, IFN alpha (Bender MedSystem, Germany, LOQ:
3.2 pg/mL, CV: 7.2 %), IFN gamma (Bender MedSystem,
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Germany, LOQ: 0.99 pg/mL, CV: 5.7 %), neopterin
(HENNING test, BRAHMS Diagnostica, Berlin, Germany,
LOQ: 0.5 ng/mL, CV: 6.9 %), β2M (Quantikine® IVD®,
R&D System, UK, LOQ: 0.2 μg/mL, CV: 7.1 %) and 2′–5′
OAS isoform 1 (USCNK Life Science, USA, LOQ <1.5 ng/
mL, CV < 12 %). In all cases, sera were stored at −70 °C
until testing. Clinical laboratory variables were tested
using advanced automated analyzers.
Data analysis
Serum concentration versus time profiles of IFN alpha-
2b and IFN gamma were analyzed using MONOLIX
(Lixoft S.A.S, version 4.3.2, 2014, Paris, France). A previ-
ous evaluation showed the combined observational mod-
eling as the most appropriated. A log-normal parameter
distribution was selected, except for absorbed fraction
(F), which was considered as logit-normal. Seven alter-
native compartmental models were evaluated, according
with the number of compartments and the complexity
of the absorption process. Table 1 describes models
considered.
The objective function for model selection was the
Akaike Information Criterion (AIC). Additionally, we
considered the coefficient of correlation between individ-
ual predicted values and actual measured concentration.
Area under the curve (AUC) was calculated by means
of the trapezoidal rule from measured individual con-
centrations and from model predicted concentration
values. AUC relative prediction error also contains in-
formation about model adequacy and is calculated as
follow.
PE %ð Þ ¼ AUCp‐AUCm
AUCm
 100
Where AUCp is the area calculated from individual pre-
dicted concentrations and AUCm is the area calculated
from measured concentration values. As a measure of
bias, we considered the mean relative prediction error
and its root mean square as precision assessment [9].




(PK/PD) model was written using the build-in MLXTRAN
code in MONOLIX, based on the best-fit PK model and a









Where R is the response, k0in is the zero order rate con-
stant for the production of response, kout is the first order
rate constant for response decrement and Cp is the serum
concentration, Smax is the maximum stimulatory factor at-
tributed to drug and SC50 is drug concentration producing
50 % of maximum stimulation.
To account for differences in response between both
IFNs related to pharmacokinetics, a delay equivalent to
the duration of zero order absorption (Tk0) was intro-
duced, manifest in the case of neopterin and β2M. For
2′–5′ OAS and body temperature, initial response level
was added to the model. A diagram to illustrate the final
adopted structural model is shown in Fig. 1.
Running integrated PK/PD model in MONOLIX, we
left constant pharmacokinetic parameters and its stand-
ard deviation (fixed and random effects) as previously
estimated, allowing the system to estimate individual
pharmacokinetic parameters and population and individ-
ual pharmacodynamic parameters.
Description of pharmacokinetic and pharmacodynamic
parameters were done using Microsoft Excel 2010
(Microsoft Corp.; USA) data analysis package. Categorical
analysis (Wald’s test) was performed with MONOLIX.
Vital signs, hematological counts and blood chemistry
were analyzed using paired analysis (Student’s t test or
Wilcoxon’s test) depending on the normality assumption,
taking into account Bonferroni adjustment for multiple
Table 1 Model description of the seven compartmental models used and estimated parameters
Model Description Parameters
I Mono-compartmental with zero order absorption and bioavailability Tk0, F, V, k
II Mono-compartmental with first order absorption and bioavailability ka, F, V, k
III Bi-compartmental with first order absorption and bioavailability ka, F, V, k, k12, k21
IV Mono-compartmental with simultaneous zero order and first order absorption Tk0, ka, F, V, k
V Mono-compartmental with consecutive zero order and first order absorption. One bioavailability value Tk0, ka, F, V, k
VI Mono-compartmental with two simultaneous first order absorptions ka1, F, ka2, V, k
VII Mono-compartmental with consecutive zero order and first order absorption. One bioavailability value for
each absorption component
Tk0, ka, F1, F2, V, k
Tk0 duration of zero order absorption, F bioavailability associated to absorption processes, V volume of distribution of central compartment, ka rate constant of
first order absorption, k first order elimination rate constant, k12 and k21: first order inter-compartmental rate constants
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comparisons. SPSS for Windows version 15.0 was the soft-
ware used for these safety analyses.
Results
Nine healthy male volunteers received the tested formu-
lation from a total of 19 subjects that were checked. This
sample size was estimated using the method for 95 %
confidence interval of a mean taken into account previ-
ous pharmacodynamic results obtained in patients with
mycosis fungoides [8]. Skin white color prevailed (66.7 %).
Their age ranged from 23 to 39 years-old (28 ± 5 years),
weighed 52 to 98 Kg (71 ± 16 Kg) and were 162 to 175 cm
(170 ± 5 cm) tall.
Pharmacokinetic analysis
The best-fit model was number V for both IFNs. Table 2
shows AIC and correlation coefficient, while Table 3
summarizes the pharmacokinetic parameters estimated
according to model V.
Figures 2 and 3 depict the relation between measured
and predicted concentration as well as the visual predic-
tion checking (VPC) according to model V for IFNs
alpha-2b and gamma, respectively. Raw data is plotted
together with VPC graph.
Interestingly, IFN gamma also fit well to model V, but
with a shorter duration of the zero order absorption step
(p < 1×10−10, Wald’s test) and a higher volume of distri-
bution (p = 0.008, Wald’s test).
Average serum IFN profiles were qualitatively similar,
although the maximum was reached 3–4 h before for
IFN gamma. IFN gamma concentrations were higher, in
agreement with the administered mass, calculated from
their respective specific activities. Pre-dose serum IFN
concentration was undetectable or very low. Most vol-
unteers bordered or surpassed 100 pg/mL of IFN alpha
and 200 pg/mL of IFN gamma.
Obtained AUC48 covered more than 96 % of AUC ex-
trapolated to infinity. Table 4 shows areas under the
curve of pharmacokinetic profiles for measured and pre-
dicted concentrations. Figure 4 represents the correlation
between actual and predicted AUC for IFN alpha-2b and
IFN gamma, respectively. It is noticeable that there is an
excellent correspondence between actual and predicted
AUC, which demonstrates the adequacy of best-fit model.
Pharmacodynamic analysis
Table 5 contains AIC and R2 for each measured response
obtained from the application of the selected model. As
observed, this model fits better in the case of IFN alpha
than in the case of IFN gamma according to AIC.
Table 6 summarizes pharmacodynamic parameters
and its variability expressed as confidence intervals. Both
IFNs were co-administered; therefore, the response due
to each IFN cannot be separated. Nonetheless, according
with our results IFN alpha-2b fits better to the selected
PK/PD model. Only for body temperature, a similar in-
crease and decrease in the response is observed when
each IFN is separately modeled.
Figures 5 and 6 depict the VPC according to the se-
lected integrated PK/PD model for IFNs alpha-2b and
gamma, respectively. It is evident the adequacy of the in-
tegrate PK/PD model for IFN alpha-2b with neopterin
and β2M, because Tk0 is almost equivalent to response
initial delay, shorter in the case of IFN gamma.
Baseline levels of biomarkers were within normal values
specified by the EIA kits suppliers. A strong neopterin
Fig. 1 Schematic PK-PD structural model for IFN response
Table 2 Values of objective function and correlation between
measured and predicted concentrations
Model IFN AIC R2
I alpha 1059 0.963
gamma 1335 0.963
II alpha 1160 0.897
gamma 1375 0.940
III alpha 1167 0.898
gamma 1380 0.941
IV alpha 1062 0.963
gamma 1373 0.956
V alpha 980 0.983
gamma 1262 0.967
VI alpha 1164 0.897
gamma 1384 0.938
VII alpha 1013 0.984
gamma 1341 0.965
AIC Akaike Information Criterion
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Table 3 Mean individual pharmacokinetic parameters and confidence intervals for IFN alpha-2b and IFN gamma (Model V)
Parameter
(units)
Definition IFN alpha-2b IFN gamma
Mean 95 % CI Mean 95 % CI
Tk0 (h) Duration of zero order absorption 5.71 5.55–5.87 2.66 2.08–3.23
ka (h–1) First order absorption rate 0.15 0.12–0.19 0.42 0.25–0.58
F Bioavailability 0.22 0.15–0.30 0.15 0.15–0.15
V (L) Volume of distribution of central compartment 38.4 38.4–38.5 118 21–214
k (h−1) First order elimination rate order 0.21 0.18–0.23 0.09 0.08–0.09
Cl (L/h) Total clearance 1.8 1.1–2.4 4.3 0.4–8.1
Fig. 2 Relation between measured and predicted IFN alpha-2b concentrations in serum. Legend: Data correspond to IFN alpha-2b concentrations
(pg/mL) measured by EIA after a single intramuscular administration of 24.5 × 106 IU of CIGB-128-A to the nine healthy male subjects, according
to model V. a Population predicted concentration. b Individual predicted concentration and (c) VPC graph
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production was obtained with co-formulated IFNs. An ap-
proximately nine-fold average increase was obtained 48 h
after CIGB-128-A administration (Figs. 5a and 6a).
Neopterin values remained clearly upper baseline levels
between 12 and 120 h. All subjects increased this marker
at least by six times compared to pre-dose values.
Average β2M approximately doubled the initial value
between 24 and 48 h after injection, and then slowly
returned to baseline at the end of the sampling period
(Figs. 5b and 6b). Maximum levels of 2′–5′ OAS1 were
achieved 6–12 h after CIGB-128-A administration;
these were around 18-fold higher than baseline.
Twelve hours later, OAS concentration was reduced,
but levels remained stable from 96 h on, being ap-
proximately four-fold higher than baseline (Figs. 5c
and 6c).
Fig. 3 Relation between measured and predicted IFN gamma concentrations in serum. Legend: Data correspond to IFN gamma concentrations
(pg/mL) measured by EIA after a single intramuscular administration of 24.5 × 106 IU of CIGB-128-A to the nine healthy male subjects, according
to model V. a Population predicted concentration. b Individual predicted concentration and (c) VPC graph
Table 4 Actual and predicted areas under the curve with its estimated bias and precision
IFN AUC (pg · h/mL) Bias
95 % CI
Precision
95 % CIActual Predicted
alpha-2b 1979 (1751–2207) 1970 (1766–2174) −0.1 (−1.8–1.6) 6.6 (3.4–9.8)
gamma 4655 (3068–6242) 4557 (3000–6114) −2.0 (−3.5–-0.5) 9.5 (2.5 – 16.5)
AUC values are reported as mean (95 % CI)
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Safety data
All volunteers presented at least one adverse event,
predominantly flu-like symptoms, but none of them
withdrew from the trial due to this or other causes.
Fever and headache were registered in all subjects.
Other manifestations such as arthralgias, lymphopenia,
tachycardia, myalgias, malaise, tremors, anorexia and
thrombocytopenia occurred in more than half of the in-
dividuals. Most events were mild (85.9 %), being well
solved. No severe adverse events were recorded.
Despite the antipyretic treatment, the increment in
body temperature was quite remarkable, reaching 39.0 °C
in eight subjects. Peak temperature values were reached
between 7 and 10 h after IFN administration (Figs. 5d
and 6d).
White cells and platelet counts were reduced below
normal values in most subjects. Particularly, mean changes
from baseline in lymphocyte count were significant
(p < 0.006) at several times, outstandingly 24 h post-
injection, when the mean value was 0.7 × 109/L. Other clin-
ical laboratory measures were not significantly affected.
Discussion
An initial zero order absorption rate, Tk0, was also ob-
served by other authors after subcutaneous administration
of IFN alpha [11]. As both IFNs are co-administered in a
single formulation, we cannot differentiate their individual
participation in the total pharmacodynamic responses. In
addition, we cannot explain the high levels of a pharmaco-
dynamic marker in blood because of the lack of empirical




























AUC from measured concentrations





























AUC from measured concentrations
a
b
Fig. 4 Correlation between actual and predicted AUC (pg · h/mL) for (a) IFN alpha-2b and (b) IFN gamma
Table 5 Criteria of integrated PK/PD model adequacy for each
measured response
IFN Criteria Neopterin β2M 2′–5′ OAS1 Temperature
alpha-2b AIC 1218 1099 2122 1593
R2 0.959 0.943 0.969 0.834
gamma AIC 1569 1334 2283 1721
R2 0.952 0.946 0.931 0.839
AIC Akaike Information Criterion
García-García et al. BMC Pharmacology and Toxicology  (2016) 17:58 Page 7 of 11
data to “fill” compartments defined in complex structural
models based on mechanistic approaches. This situation is
very common in clinical trials [12], like the present study.
Pharmacodynamics of CIGB-128-A formulation was
characterized through three well-known IFN response
markers, mediators of their main biological actions, trad-
itionally used in this type of studies [13, 14]. Neopterin
is an excellent marker of the immune-mediated cytotox-
icity and induction of apoptosis in human malignancies
[15]. Beta2-microglobulin plays a key role in tumor
growth control and metastases [16]. The 2′–5′OAS en-
zyme interferes in the progression of the cell cycle [17]
and produces degradation of viral RNA [18].
The delayed irruption of neopterin and β2M responses
is commonly explained as a consequence of the complex
intracellular pathways triggered after IFN binding to its
surface receptor. This concept was successfully applied
to the stimulation of the synthesis of the antiviral Mx
protein by IFN alpha-2a subcutaneous administration to
healthy volunteers [19].
Working with the obtained data, delay in neopterin
and β2M responses could be related to Tk0. Existence of
zero order absorption has been suggested to occur owing
to saturated absorption just after administration [11]. Dif-
ferences in molecular structure, consequently in physico-
chemical characteristics, can be a plausible cause for
differences in absorption between IFNs alpha and gamma.
However, a delay was not observed for the other mea-
sured responses (2′–5′ OAS, temperature) which could
obey to different triggering mechanisms [20]. Quantifica-
tion of serum or plasma 2′–5′ OAS by EIA (instead of
intracellular expression or enzymatic activity) to evaluate
pharmacodynamics in humans is not easily identified in
literature. Body temperature was used as pharmacody-
namic variable as well, although its increment consti-
tutes an undesired effect. IFN alpha induces fever, at
least partly due to direct effects on the hypothalamic
thermosensitive neurons, which involve also the opiate
receptor mechanism [21]; while IFN gamma stimulates
the release of pyrogenic interleukin-1 [22].
On the other hand, there are no data indicating interfer-
ences in the pharmacokinetic profiles of IFNs alpha-2b
and gamma when they are simultaneously administered.
Our findings reveal a pharmacokinetic behavior of IFN
alpha-2b quite similar to that reported by other authors
[11]. Distribution to a wide range of tissues and organs
and a very fast clearance are distinctive characteristics of
IFNs [23–27].
Despite IFNs antitumor activity being well-known at
present, no major advances have been achieved in the
treatment of solid and hematological malignancies in the
last decades. An enhanced survival or a better objective
response cannot be achieved by a dose increment since
more severe adverse reactions could irrupt. Additionally,
a more prolonged schedule reduces patient’s compliance.
A sustained full IFN-receptor interaction that triggers
strong antiproliferative activities is desired in the cancer
treatment with this cytokine. The slow systemic clear-
ance of PEG-IFN alpha structures had led to less dosing,
more efficacy and less toxicity in patients with chronic
viral hepatitis [28]. However, pegylation produces a
notable reduction in IFN bioactivity [29], probably due
to a non-optimal interaction with its receptor. Add-
itionally, high molecular weight pegylated IFNs could
have more difficulties to penetrate into the tumor
microenvironment and have an effective interaction
with its receptor.
The combination of co-formulated IFNs alpha and
gamma could improve antitumor effects of separate
IFNs. CIGB-128-A formulation was developed on the basis
of two essential criteria; first, the in vitro and in vivo po-
tentiation of common biological activities of IFN alpha-2b
and IFN gamma in certain proportions previously defined
[6, 30] and second, their similar pharmacokinetics.
Table 6 Mean individual pharmacodynamic parameters and
confidence intervals for IFNs alpha-2b and gamma
Parameter
(units)
IFN alpha-2b IFN gamma
Mean 95 % CI Mean 95 % CI
Neopterin
Smax 25.8 25.2–26.4 16.7 15.8–17.6
SC50 (pg/mL) 15.5 14.8–16.1 19.5 13.8–25.3
kin (h
−1) 0.027 0.024–0.030 0.03 0.026–0.034
kout (h
−1) 0.022 0.022–0.022 0.0247 0.0247–0.0248
β2-microglobulin
Smax 1.03 0.95–1.1 4.5 3.81–5.1
SC50 (pg/mL) 0.31 0.03–0.58 76.4 37.2–115.7
kin (h
−1) 0.141 0.133–0.149 0.04 0.033–0.038
kout (h
−1) 0.070 0.067–0.073 0.0194 0.0190–0.0198
2′–5′ oligoadenylate synthetase
S0 (ng/mL) 33.9 14.5–53.3 762 721–803
Smax 25.8 10.6–41.0 104 39–169
SC50 (pg/mL) 419 392–446 730 394–1066
kin (h
−1) 1990 1754–2226 237 188–285
kout (h
−1) 28.20 14.21–42.18 17.7 6.2–29.1
Body temperature
S0 (°C) 35.9 35.9–35.9 36.2 36.0–36.2
Smax 9.7 9.5–9.8 7.2 6.7–7.6
SC50 (pg/mL) 252 239–264 374 254–493
kin (h
−1) 0.864 0.858–0.870 0.851 0.848–0.855
kout (h
−1) 1.0155 1.015–1.016 1.021 1.021–1.021
S0 baseline response, Smax maximum stimulatory factor attributed to drug,
SC50: drug concentration producing 50 % of maximum stimulation, kin the zero
order rate constant for the production of response, kout the first order rate
constant for loss of response
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Fig. 5 Model validation and raw data of pharmacodynamic variables for IFN alpha-2b. Legend: Data correspond to the nine healthy male
subjects who received 24.5 × 106 IU of CIGB-128-A at time 0. a Neopterin. b β2M. c 2′–5′ OAS1 and (d) Body temperature (first 48 h).
Raw data is plotted together with VPC graph























































































Fig 6 Model validation and raw data of pharmacodynamic variables for IFN gamma. Legend: Data correspond to the nine healthy male subjects
who received 24.5 × 106 IU of CIGB-128-A at time 0. a Neopterin. b β2M. c 2′–5′ OAS1 and (d) Body temperature (first 48 h). Raw data is plotted
together with VPC graph
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The high increments in serum neopterin levels in
healthy subjects could support the hypothesis on which
CIGB-128-A formulation was conceived. That nine-fold
neopterin increase has not been reported with any sub-
type or variant of IFN. After a single intramuscular dose
of 18 × 106 IU IFN beta to healthy volunteers, serum
neopterin increments were five-fold higher than baseline
levels [13], leading to a lower Smax in a later modeling
analysis [31]. Single subcutaneous doses of 27 and 36 × 106
IU of IFN alpha-2a to healthy volunteers only produced
four-fold increments in plasma neopterin concentrations
[32]. The induction of neopterin by PEG-IFN alpha in pa-
tients or healthy volunteers only approximately tripled the
initial values, 48 h after injection [14, 33, 34]. Pegylation
seems to produce a reduction in Smax as occurred with Mx
protein [19]. In the previous clinical trial in patients with
mycosis fungoides, intramuscular 23 × 106 IU of the co-
formulated IFNs produced neopterin increments that were
six-fold higher at the same sampling time [8].
Beta2-microglobulin increments are around 60 % after
administration of PEG-IFN alpha [14, 34], lower than
100 % found 24–48 h after CIGB-128-A injection. Al-
though this last increment was reached in a similar popula-
tion after administration of 20 ×106 IU of IFN alpha-2b
[27], a slower return to initial levels was now observed.
Six hours after a single CIGB-128-A intramuscular
injection, 2′–5 OAS1 serum levels were extensively in-
creased in healthy volunteers. In IFN-treated patients,
enzymatic activity of 2′–5 OAS appears to increase
since 6 h and maintains elevated levels until 4–8 months
later during chronic treatments [35]. OAS induced by
CIGB-128-A continued detectable until 192 h and the
moment to return to normality could not be predicted.
Nevertheless, we need to deepen into the mechanisms
that trigger all these responses allowing us to explain the
postulated enhanced effect. There are other factors
making this task difficult, mainly those related to
administered doses, like response saturation [32].
Pharmacodynamic findings were part of the overall in-
formation that justified approval of further clinical trials
with CIGB-128-A formulation. In these trials more spaced
dosing schedules are evaluated in patients with advanced
or metastatic solid tumors without other therapeutic
options. These are ongoing trials and preliminary results
are encouraging.
The formulation was well tolerated. As expected, flu-like
symptoms and hematological count reductions were the
most common adverse events generated after administra-
tion. Bone marrow depression produced after only one IFN
dose can be explained by increase in cortisol levels [36].
Conclusions
In this work PK/PD of CIGB-128-A formulation, contain-
ing IFNs alpha 2b and gamma co-formulated in synergistic
proportions, was characterized. The PK best-fit model was
number V for both IFNs and average serum IFN profiles
were qualitatively similar. Compared with literature data
CIGB-128-A promotes strong neopterin and 2–5 OAS
production and extends upper baseline levels until 98 and
120 h, respectively. A unique dose of more than 20 MIU
of CIGB-128A was safe with no severe event reported.
These properties indicate that this formulation is a good
candidate to treat some oncologic diseases, without phar-
macokinetic interferences or additional toxicity.
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